Pacira BioSciences (PCRX) Gains from Investment Securities (2019 - 2026)

Pacira BioSciences' Gains from Investment Securities history runs 8 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• On a quarterly basis, Gains from Investment Securities rose 15.67% year-over-year to -$2.3 million in Q1 2026; TTM through Mar 2026 was -$1.8 million, a 46.97% increase from a year earlier, with the FY2025 full-year figure at -$2.2 million, up 51.2% from the prior year.
• Gains from Investment Securities eased to -$2.3 million in Q1 2026 per PCRX's latest filing, from $232000.0 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $12.5 million in Q2 2022 and bottomed at -$18.3 million in Q2 2023.
• The 5-year median for Gains from Investment Securities is $232000.0 (2025), against an average of -$385058.8.
• Biggest YoY gain for Gains from Investment Securities was 12400.0% in 2022; the steepest drop was 606.83% in 2022.
• Year by year, Gains from Investment Securities stood at -$6.1 million in 2022, then jumped by 106.95% to $423000.0 in 2023, then soared by 156.26% to $1.1 million in 2024, then tumbled by 78.6% to $232000.0 in 2025, then plunged by 1081.47% to -$2.3 million in 2026.
• Per Business Quant, the three latest PCRX Gains from Investment Securities figures stand at -$2.3 million (Q1 2026), $232000.0 (Q4 2025), and $625000.0 (Q3 2025).